Ftse Mib
33.414,56
0,46%
DAX
19.626,45
1,05%
S&P 500
6.032,38
0,56%
NASDAQ
19.218,17
0,83%
Bitcoin
96.487,72
-1,02%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. AMEX Can Fite BioPharma Ltd (CANF) Can Fite BioPharma Ltd (CANF) Notizie

CANF

Can Fite BioPharma (CANF)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:AMEX:CANF
DataOraFonteTitoloSimboloCompagnia
14/11/202422:48Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]AMEX:CANFCan Fite BioPharma Ltd
11/11/202413:00GlobeNewswire Inc.Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical TrialAMEX:CANFCan Fite BioPharma Ltd
04/11/202413:09Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
04/11/202413:08GlobeNewswire Inc.Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in AustraliaAMEX:CANFCan Fite BioPharma Ltd
18/10/202415:06GlobeNewswire Inc.Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with PiclidenosonAMEX:CANFCan Fite BioPharma Ltd
09/10/202413:00GlobeNewswire Inc.FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic CancerAMEX:CANFCan Fite BioPharma Ltd
07/10/202413:00GlobeNewswire Inc.Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29AMEX:CANFCan Fite BioPharma Ltd
24/09/202413:00GlobeNewswire Inc.Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary OsteoarthritisAMEX:CANFCan Fite BioPharma Ltd
16/09/202413:00GlobeNewswire Inc.Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of HealthAMEX:CANFCan Fite BioPharma Ltd
09/09/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:CANFCan Fite BioPharma Ltd
06/09/202422:30Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]AMEX:CANFCan Fite BioPharma Ltd
30/08/202422:18Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersAMEX:CANFCan Fite BioPharma Ltd
30/08/202422:16Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementAMEX:CANFCan Fite BioPharma Ltd
30/08/202422:15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:CANFCan Fite BioPharma Ltd
29/08/202414:15GlobeNewswire Inc.Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical StudiesAMEX:CANFCan Fite BioPharma Ltd
09/08/202401:01GlobeNewswire Inc.Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross ProceedsAMEX:CANFCan Fite BioPharma Ltd
29/07/202413:00GlobeNewswire Inc.Can-Fite Provides Namodenoson Patent UpdateAMEX:CANFCan Fite BioPharma Ltd
17/07/202413:00GlobeNewswire Inc.Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8AMEX:CANFCan Fite BioPharma Ltd
11/07/202413:00GlobeNewswire Inc.Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic CancerAMEX:CANFCan Fite BioPharma Ltd
01/07/202413:00GlobeNewswire Inc.Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with NamodenosonAMEX:CANFCan Fite BioPharma Ltd
28/06/202413:00Business WirePositive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner VetbiolixAMEX:CANFCan Fite BioPharma Ltd
24/06/202413:00Business WireCan-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the LiverAMEX:CANFCan Fite BioPharma Ltd
10/06/202413:00Business WireCan-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa StudyAMEX:CANFCan Fite BioPharma Ltd
07/06/202422:15Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]AMEX:CANFCan Fite BioPharma Ltd
05/06/202413:00Business WireCan-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 StudyAMEX:CANFCan Fite BioPharma Ltd
29/05/202413:00Business WireIndependent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart DiseasesAMEX:CANFCan Fite BioPharma Ltd
27/05/202413:00Business WireCan-Fite to Participate in Partnering Meetings at Bio International Convention 2024AMEX:CANFCan Fite BioPharma Ltd
23/05/202413:00Business WireJoin Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6AMEX:CANFCan Fite BioPharma Ltd
13/05/202413:00Business WireCan-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer StudyAMEX:CANFCan Fite BioPharma Ltd
09/05/202413:00Business WireCan-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb StudyAMEX:CANFCan Fite BioPharma Ltd
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:AMEX:CANF

La tua Cronologia

BOV
HOSI11
Fundo DE Investimento Im...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network